For Immediate Release: January 30, 2025 Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a...

BOSTON--(BUSINESS WIRE)--Jan. 30, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration...

Food and Drug Administration (FDA) approved a new medication called Journavx (suzetrigine) to treat moderate to severe acute pain in adults. This...

FDA approves Journavx, a non-opioid medication for moderate to severe acute pain. Learn about its efficacy and side effects.

FRIDAY, Jan. 31, 2025 -- The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or...

Suzetrigine (Journavx) is the first non-opioid pain medication to be approved in the US in 20 years. It could help over 80 million Americans living...

FRIDAY, Jan. 31, 2025 -- The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or...

Suzetrigine (Journavx) is the first non-opioid pain medication to be approved in the US in 20 years. It could help over 80 million Americans living...

Oral drug from Vertex, branded as Journavx, represents alternative to addictive opioids that have fueled US crisis

The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive.